Oral obesity treatment stocks Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:31
Jan 06
Jan 06
Oral obesity market expands, Novo benefits.
Novo Nordisk's oral Wegovy treatment is gaining momentum and could be priced at around 300,000 won per month, making obesity treatment more accessible. The speaker expects oral obesity treatment-related stocks to remain favorable.
MED
About Oral obesity treatment stocks Investor Commentary
Across the available history and selected sources, Buzzberg tracks Oral obesity treatment stocks across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Ji-eun.